


HDAC6-IN-12

Cat. No.:	HY-150722
CAS No.:	2803866-44-4
Molecular Formula:	C ₂₄ H ₃₉ F ₂ N ₃ O ₅
Molecular Weight:	487.58
Target:	HDAC
Pathway:	Cell Cycle/DNA Damage; Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	HDAC6-IN-12 (compound GZ) is a potent HDAC6 inhibitor. HDAC6-IN-12 has anticancer activity through merges into DNA strands causing DNA damage. HDAC6-IN-12 can be used for cancer research ^[1] .								
In Vitro	<p>HDAC6-IN-12 (compound GZ) (72 h) has anti-proliferative activity on tumor cells against HuH-7, HeLa, MDA-MB-231, SKOV3, A549, PANC-1, HCT-116, SGC7901 and 4T1 cells with IC₅₀ values of 0.12 μM, 0.43 μM, 0.14 μM, 0.62 μM, 0.14 μM, 1.08 μM, 0.30 μM, 3.70 μM and 0.66 μM, respectively^[1].</p> <p>HDAC6-IN-12 (compound GZ) (0-3 μM; 24 h; MBA-MB-231 cells) merges into DNA strands causing DNA damage and increases the level of phospho-γ-H2A.X, which is the marker of DNA strand break^[1].</p> <p>HDAC6-IN-12 (compound GZ) (0-100 μM; 30 min) has major metabolic enzymes including CYP3A2, CYP1A1/2 isoforms^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Western Blot Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>MBA-MB-231 cells</td> </tr> <tr> <td>Concentration:</td> <td>0, 0.1, 0.3, 1 and 3 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 hours</td> </tr> <tr> <td>Result:</td> <td>Increased the level of phospho-γ-H2A.X in a dose-dependent manner.</td> </tr> </table>	Cell Line:	MBA-MB-231 cells	Concentration:	0, 0.1, 0.3, 1 and 3 μM	Incubation Time:	24 hours	Result:	Increased the level of phospho-γ-H2A.X in a dose-dependent manner.
Cell Line:	MBA-MB-231 cells								
Concentration:	0, 0.1, 0.3, 1 and 3 μM								
Incubation Time:	24 hours								
Result:	Increased the level of phospho-γ-H2A.X in a dose-dependent manner.								
In Vivo	<p>HDAC6-IN-12 (compound GZ) (5-10 mg/kg; i.p.; once every three days, for 15 d; babc female mice) inhibits tumor growth in a dose-dependent manner^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Babc female mice^[1]</td> </tr> <tr> <td>Dosage:</td> <td>5 and 10 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal injection; once every three days, for 15 days</td> </tr> <tr> <td>Result:</td> <td>Inhibited tumor growth with TGI of 73.2% at 5 mg/kg and 83.8% at 10 mg/kg, respectively.</td> </tr> </table>	Animal Model:	Babc female mice ^[1]	Dosage:	5 and 10 mg/kg	Administration:	Intraperitoneal injection; once every three days, for 15 days	Result:	Inhibited tumor growth with TGI of 73.2% at 5 mg/kg and 83.8% at 10 mg/kg, respectively.
Animal Model:	Babc female mice ^[1]								
Dosage:	5 and 10 mg/kg								
Administration:	Intraperitoneal injection; once every three days, for 15 days								
Result:	Inhibited tumor growth with TGI of 73.2% at 5 mg/kg and 83.8% at 10 mg/kg, respectively.								

REFERENCES

[1]. Li Y, et, al. Design, synthesis and antitumor activity study of a gemcitabine prodrug conjugated with a HDAC6 inhibitor. Bioorg Med Chem Lett. 2022 Sep 15;72:128881.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA